Press Releases Neurogene Inc.

Stocks

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/06/2026 BST			5-day change	1st Jan Change
28.60 ^USD	+7.97%		+3.85%	+38.83%

06-08	Neurogene Completes Dosing in Embolden Registrational Trial of Ngn-401 for Rett Syndrome	CI
06-08	Neurogene Completes Enrollment in Embolden Trial of NGN-401	MT

Press Releases

06-08	Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome	BU
06-02	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05-12	Neurogene : Corporate Presentation May 2026	PU
05-12	Neurogene: Q1 Earnings Snapshot	AQ
05-12	Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates	BU
05-12	Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy	BU
05-06	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04-28	Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy	BU
04-20	Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors	BU
04-08	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
03-24	Neurogene: Q4 Earnings Snapshot	AQ
03-24	Neurogene : Corporate Presentation March 2026	PU
03-24	Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates	BU
03-11	Neurogene to Participate in Stifel 2026 Virtual CNS Forum	BU
03-03	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
02-26	Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome	BU
02-05	Neurogene to Participate in Upcoming Investor Conferences	BU
02-04	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	BU
01-14	Neurogene : 2026 JP Morgan Presentation	PU
01-12	Neurogene : Corporate Presentation January 2026	PU
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome	BU
01-05	Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
12-04	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11-13	Neurogene : 202511 NGNE Corporate Presentation	PU
11-13	Neurogene: Q3 Earnings Snapshot	AQ